With GSK eager for marketing approval, Shingrix passes revaccination test

22nd June 2017 Uncategorised 0

Awaiting a potential FDA approval, GlaxoSmithKline’s much-anticipated shingles vaccine Shingrix met its goal in a phase 3 study examining whether it can protect older adults who have previously received Merck’s Zostavax.

More: With GSK eager for marketing approval, Shingrix passes revaccination test
Source: fierce